MiNK Therapeutics Files 8-K on Financials
Ticker: INKT · Form: 8-K · Filed: May 14, 2024 · CIK: 1840229
Sentiment: neutral
Topics: financial-reporting, corporate-actions
TL;DR
MiNK Therapeutics dropped an 8-K on financials, check it out.
AI Summary
MiNK Therapeutics, Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company was formerly known as AgenTus Therapeutics, Inc. before changing its name on January 12, 2021.
Why It Matters
This 8-K filing provides an update on MiNK Therapeutics' financial status and operational results, which is crucial information for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any significant new risks or negative developments.
Key Players & Entities
- MiNK Therapeutics, Inc. (company) — Registrant
- AgenTus Therapeutics, Inc. (company) — Former company name
- May 14, 2024 (date) — Date of report
- January 12, 2021 (date) — Date of name change
FAQ
What specific financial information is being reported in this 8-K?
The 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was MiNK Therapeutics, Inc. previously known by another name?
MiNK Therapeutics, Inc. was formerly known as AgenTus Therapeutics, Inc., with the name change occurring on January 12, 2021.
What is the principal executive office address for MiNK Therapeutics, Inc.?
The principal executive offices are located at 149 Fifth Avenue, Suite 500, New York, New York 10010.
What is the SIC code for MiNK Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for MiNK Therapeutics, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
What is the Commission File Number for MiNK Therapeutics, Inc.?
The Commission File Number for MiNK Therapeutics, Inc. is 001-40908.
Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-05-14 07:30:18
Key Financial Figures
- $0.00001 — ange on which registered Common Stock, $0.00001 par value per share INKT The NASDAQ Cap
Filing Documents
- f8k_051424.htm (8-K) — 14KB
- exh_991.htm (EX-99.1) — 28KB
- 0001171843-24-002826.txt ( ) — 244KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_051424_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On May 14, 2024, MiNK Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2024. In connection with the announcement, the Company issued a press release, which is being furnished as Exhibit 99.1 to this current report on Form 8-K. The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibit The following exhibit is furnished herewith: 99.1 Press Release dated May 14, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MiNK Therapeutics, Inc. Date: May 14, 2024 By: /s/ Christine M. Klaskin Christine M. Klaskin Principal Financial Officer